“Impact of the Modulator Elexacaftor Tezacaftor Ivacaftor (ETI) on the Complexity of Prescriptions and the Clinical Stage of Children and Adolescents With Cystic Fibrosis”. Research, Society and Development 15, no. 1 (January 28, 2026): e7715150550. Accessed February 3, 2026. https://rsdjournal.org/rsd/article/view/50550.